SCHEMBL2483579

SCHEMBL2483579

Clc1cccc(Cl)c1C=NCCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.51
ALDH1A1 P00352 4/20 0.51
GAA P10253 3/20 0.51
MAPT P10636 2/20 0.49
HTT P42858 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
CA1 P00915 4/20 0.45
CA2 P00918 4/20 0.45
CA9 Q16790 4/20 0.45
CA12 O43570 2/20 0.45
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2C19 P33261 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CA7 P43166 2/20 0.43
SHBG P04278 1/20 0.41
SLC22A1 O15245 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2483578 1.00 TAAR1 (0.51) TAAR1ALDH1A1GAAMAPTHTT
SCHEMBL10688866 0.81 MAPT (0.49) TAAR1ALDH1A1GAAMAPTHTT
SCHEMBL2486006 0.76 SLC22A1 (0.47) TAAR1ALDH1A1GAAMAPTHTT
SCHEMBL2486005 0.76 SLC22A1 (0.47) TAAR1ALDH1A1GAAMAPTHTT
SCHEMBL3067896 0.75 TAAR1 (0.70) TAAR1ALDH1A1GAAMAPTHTT
SCHEMBL3067898 0.75 TAAR1 (0.70) TAAR1ALDH1A1GAAMAPTHTT
SCHEMBL8418689 0.75 TAAR1 (0.76) TAAR1ALDH1A1GAAMAPTCA1
SCHEMBL2464453 0.75 TAAR1 (0.76) TAAR1ALDH1A1GAAMAPTCA1
SCHEMBL30342907 0.75 TAAR1 (0.58) TAAR1ALDH1A1GAAMAPTHTT
SCHEMBL14676823 0.72 TAAR1 (0.57) TAAR1ALDH1A1GAACA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1017358-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2004-08-11 EP claimed
EP-1017358-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-07-12 EP claimed
US-5939458-A APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN GILLETTE COMPANY, THE 1999-08-17 US claimed
WO-1999015136-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 1999-04-01 WO claimed
CN-107106533-B Synergistic composition for treating microbial infections 罗切斯特大学 2020-11-06 CN disclosed
EP-3212183-B1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIV ROCHESTER (US) 2019-10-02 EP disclosed
US-10028931-B2 Synergistic compositions for treating microbial infections UNIVERSITY OF ROCHESTER (US) 2018-07-24 US disclosed
EP-3212183-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS University of Rochester (US) 2017-09-06 EP disclosed
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIVERSITY OF ROCHESTER (US) 2017-08-31 US disclosed
WO-2016070021-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS UNIVERSITY OF ROCHESTER (US) 2016-05-06 WO disclosed
US-8778631-B2 Mono charging system for selectively introducing non-native amino acids into proteins using an in vitro protein synthesis system SUTRO BIOPHARMA, INC. (US) 2014-07-15 US disclosed
EP-2376647-B1 MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM SUTRO BIOPHARMA INC (US) 2014-03-05 EP disclosed
US-20100184135-A1 MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM SUTRO BIOPHARMA, INC. (US) 2010-07-22 US disclosed
US-20100184134-A1 DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD SUTRO BIOPHARMA, INC. (US) 2010-07-22 US disclosed
WO-2010081111-A1 MONO CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO PROTEIN SYNTHESIS SYSTEM SUTRO BIOPHARMA, INC. (US) 2010-07-15 WO disclosed
WO-2010081110-A1 DUAL CHARGING SYSTEM FOR SELECTIVELY INTRODUCING NON-NATIVE AMINO ACIDS INTO PROTEINS USING AN IN VITRO SYNTHESIS METHOD SUTRO BIOPHARMA, INC. (US) 2010-07-15 WO disclosed
EP-1017358-B1 REDUCTION OF HAIR GROWTH GILLETTE CO (US) 2004-08-11 EP disclosed
EP-1017358-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 2000-07-12 EP disclosed
US-5939458-A APPLYING AN INHIBITOR OF AMINOACYL-TRNA SYNTHETASE TO THE SKIN GILLETTE COMPANY, THE 1999-08-17 US disclosed
WO-1999015136-A1 REDUCTION OF HAIR GROWTH THE GILLETTE COMPANY (US) 1999-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10028931-B2 Synergistic compositions for treating microbial infections RNASE1, RNASEL, RNASEH1 TAAR1 4525/4885ALDH1A1 3822/4885GAA 416/4885
US-20170246139-A1 SYNERGISTIC COMPOSITIONS FOR TREATING MICROBIAL INFECTIONS RNASE1, RNASEL, RNASEH1 TAAR1 4525/4885ALDH1A1 3822/4885GAA 416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.